PGHL2024-07-012024-09-30 PGHL2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member PGHL2024-09-30 PGHL2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500126 PGHL PGHL Procter & Gamble Health Limited Equity 2024-07-01 2025-06-30 2024-11-04 2024-09-27 INR Lakhs First quarter 14:08:00 17:41:00 2024-11-04 2024-11-04 Not applicable Single segment PHARMACEUTICALS 2024-07-01 2024-09-30 Unaudited Standalone 3134100000.00 32800000.00 3166900000.00 481700000.00 201600000.00 197200000.00 462200000.00 1500000.00 57700000.00 651000000.00 2052900000.00 1114000000.00 0.00 1114000000.00 279500000.00 11200000.00 290700000.00 0.00 823300000.00 0.00 0.00 0.00 0.00 823300000.00 1700000.00 825000000.00 0.00 0.00 166000000.00 10 49.60 49.60 0.00 0.00 49.60 49.60 0.00 0.00 0.00 1. The above unaudited results have been reviewed by Audit Committee and approved by the Board of Directors of the Company at meeting held on 4th November, 2024 and have been subjected to a limited review by the Statutory Auditors of the Company. 2. Results for all above period have been prepared in accordance with Indian Accounting Standards ( Ind AS ) as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended. 3. During the previous year, certain employees opted for the Company’s existing voluntary retirement scheme. Employee cost includes expense amounting to Rs. 144 lakhs for the preceding quarter ended 30th June 2024, Rs. 1447 lakhs for the corresponding quarter ended 30th September 2023 and Rs. 3002 lakhs for the year ended 30th June 2024. 4. During the previous year, the Company discontinued production of injections at its manufacturing plant in Goa effective 30th September, 2023, as the Company started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter ended 30th June,2024 the Company entered into an agreement for sale of the assets of its injection plant for a consideration of Rs. 790 Lakhs and impaired the balance amount of Rs. 627 Lakhs. Based on above, the company has re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount of Rs. 1392 Lakhs. The above total amount of Rs. 2019 Lakhs have been disclosed as an exceptional item for the quarter and the year ended June 30, 2024. 5. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided. 6. Previous period figures have been regrouped/ reclassified wherever necessary. The figures for the preceding 3 months ended 30th June, 2024 are the balancing figures between the audited figures in respect of the full financial year ended 30th June 2024 and the year to date figures upto the third quarter of that financial year. 7. The Company does not have a subsidiary, an associate or a joint venture as at 30th September, 2024. Other Expenses 651000000.00 Re-measurement gains/(losses) on defined benefit plans 2300000.00 2300000.00 600000.00 0.00